Synthesis of trypsin-resistant variants of the Listeria-active bacteriocin salivaricin P by O'Shea, Eileen F. et al.
1NOTICE: this is the author’s version of a work that was accepted for publication in1
Applied and Environmental Microbiology. Changes resulting from the publishing2
process, such as peer review, editing, corrections, structural formatting, and other3
quality control mechanisms may not be reflected in this document. A definitive4
version was subsequently published in Appl. Environ. Microbiol. 2010, 76:5356-5
5362; doi:10.1128/AEM.00523-106
7
Synthesis of trypsin-resistant variants of the Listeria-active bacteriocin8
salivaricin P9
10
Eileen F. O’ Shea1, 3, Paula M. O’ Connor1, 2, Paul D. Cotter1,2, R. Paul Ross1, 2 and11
Colin Hill2, 312
13
1Teagasc, Moorepark Food Research Centre, Fermoy, Co. Cork, Ireland.14
2Alimentary Pharmabiotic Centre, Cork, Ireland.15
3Department of Microbiology, University College Cork, Ireland.16
17
* Corresponding author:18
Paul Ross,19
Biotechnology Department,20
Teagasc, Moorepark Food Research Centre,21
Fermoy, Co. Cork, Ireland.22
Email: paul.ross@teagasc.ie23
Tel: +353 (0)25 4222924
Fax: +353 (0)25 4234025
26
Running title: Trypsin-resistant salivaricin variants27
Keywords: Salivaricin P, Bacteriocin, Variant, Trypsin, Gastrointestinal tract.28
2Abstract29
Two-component Salivaricin P-like bacteriocins have demonstrated potential as30
antimicrobials capable of controlling infections in the gastrointestinal tract (GIT). The31
anti-Listeria activity of salivaricin P is optimal when the individual peptides, Sln1 and32
Sln2, are added in succession in a 1:1 ratio. However, as degradation by digestive33
proteases may compromise the functionality of these peptides within the GIT we34
investigated the potential to create salivaricin variants with enhanced resistance to the35
intestinal protease, trypsin. A total of 11 variants of the salivaricin P components were36
generated in which conservative modifications at the trypsin-specific cleavage sites37
were explored in order to protect the peptides from trypsin degradation while38
maintaining their potent antimicrobial activity. Analysis of these variants revealed that39
eight were resistant to trypsin digestion while retaining antimicrobial activity.40
Combining the complementary trypsin resistant variants Sln1-5 and Sln2-3 resulted in41
a MIC50 of 300 nM against Listeria monocytogenes, a 3.75-fold reduction in activity42
compared to wild-type salivaricin P. This study demonstrates the potential of43
engineering bacteriocins variants which are resistant to specific protease action but44
which retain significant antimicrobial activity.45
3Introduction46
Salivaricin P is a two-component class IIb bacteriocin produced by the porcine47
intestinal isolate Lactobacillus salivarius DPC6005, whose target specificity includes48
the food-borne intestinal pathogen Listeria monocytogenes (2). Production of49
salivaricin P-like bacteriocins is a common feature amongst Lactobacillus salivarius50
strains of intestinal origin (2) and it is evident that these bacteriocins may play an51
important role within the gut. This is demonstrated by the in vivo protection provided52
against Listeria monocytogenes infection by the salivaricin P-like bacteriocin, abp11853
(5). Production of salivaricin P is also likely to be responsible for the dominance of54
Lb. salivarius DPC6005 within the porcine ileum following its co-administration with55
four other probiotics (33). Despite this, there would seem to be potential to further56
augment salivaricin P activity in the gut as, following oral administration of the Lb.57
salivarius DPC6005 to mice, it was possible to detect the strain, but not the58
bacteriocin, in murine caecal samples (O’Shea, unpublished data).59
The proteinacious nature of bacteriocins makes them vulnerable to proteolysis60
by gut-associated proteases. This can be regarded as a beneficial trait in that it helps to61
ensure that bacteriocins used as food preservatives don’t negatively impact the natural62
gut microbiota. Conversely, it may compromise the efficacy of narrower spectrum63
bacteriocins deployed to control gastrointestinal tract (GIT) infections. As a result,64
approaches to improve the delivery and bioavailability of bacteriocins within the GIT65
have been under investigation. One option is encapsulation. Indeed encapsulated OR-66
7, a bacteriocin produced by Lb. salivarius NRRL B-30514, has demonstrated67
bioactivity in vivo and successfully reduced Campylobacter colonization in poultry68
(30). Theoretically, engineering of a bacteriocin to reduce its sensitivity to proteases is69
also a viable option. Engineering of bacteriocins has been used to generate variants70
4which have helped scientists to better understand structure-function relationships of71
these peptides (6, 7, 10, 11, 14, 24, 25, 28, 31, 34), and there have been recent72
successes in which the antimicrobial activity of bacteriocins has been enhanced73
through a bioengineering-based approach (1, 8, 9, 15, 17, 19, 35). Despite this,74
bioengineered peptides with enhanced protease-resistance have only been generated in75
the case of the class I bacteriocin, gallidermin. Unfortunately, however, the alterations76
that enhanced the protease resistance of two gallidermin analogues were found to be77
detrimental with respect to the associated antimicrobial activity (26) . In this study we78
sought to generate engineered bacteriocins that are better suited to resisting the harsh79
environment of the GIT, without compromising their antimicrobial activity. More80
specifically, our aim was to increase the resistance of the two component peptides of81
salivaricin P, Sln1 and Sln2 (both required for optimal antimicrobial activity), to82
proteolysis by the gastric protease trypsin, without significantly reducing their83
antimicrobial activity. Trypsin specifically cleaves peptides at the carboxyl side of84
lysine and arginine residues, unless followed by a proline (18). Consequently, a series85
of variants of both the Sln1 and Sln2 peptides were designed to potentially resist86
trypsin digestion as a result of incorporating amino acid substitutions at trypsin87
specific cleavage sites or insertion of proline residues following these sites. In88
addition to creating a number of engineered peptides which provide an important89
insight into the structure-function relationships of these peptides, we were successful90
in generating a variety of trypsin resistant derivatives of both peptides which retain91
significant antimicrobial potency. This represents the first example of the use of92
peptide engineering to specifically target and create trypsin resistant bacteriocins.93
94
Materials and Methods95
5Bacterial strains and culture conditions. Lactobacillus salivarius DPC600596
and Lactobacillus bulgaricus LMG 6901 were routinely grown in MRS (Difco97
Laboratories, Detroit, MI) at 37°C anaerobically. Listeria innocua DPC3572, Listeria98
monocytogenes NCTC 11994 and Enterococcus faecalis DPC1142 were grown in99
M17 (Difco) supplemented with 0.5% glucose (GM17) at 37°C aerobically, and100
GM17 supplemented with 0.1% [vol/vol] Tween 80 (Sigma, Poole, Dorset, UK) was101
used for the microtiter plate assay system.102
103
Synthesis and purification of the salivaricin P peptides. Natural salivaricin104
P Sln1 and Sln2 peptides were purified from an overnight culture of Lb. salivarius105
DPC6005 as described previously (2). The salivaricin P peptides were also106
synthesised according to the amino acid sequence reported by Barrett et al., 2007 (2)107
using microwave-assisted solid phase peptide synthesis (MW-SPPS) performed on a108
CEM LibertyTM microwave peptide synthesiser using a H-Leu-HMPB-ChemMatrix®109
resin and a H-His (Trt)-HMPB-ChemMatrix® resin (PCAS Biomatrix Inc. Quebec,110
Canada) for Sln1 and Sln2 (and corresponding variants), respectively. The111
antimicrobial activity of the peptides was confirmed by well diffusion assay as112
previously described (29). The synthetic peptides were purified by RP-HPLC using a113
Jupiter C5 (10u 300Å) column (Phenomenex, Cheshire, United Kingdom) developed114
in a gradient from 25% (vol/vol) acetonitrile containing 0.1% trifluoroacetic acid115
(TFA) to 50% (vol/vol) acetonitrile containing 0.1% TFA from 10 to 40 min at a flow116
rate of 3.5 ml/min. Absorbance was monitored at a wavelength of 214 nm. Fractions117
containing peptides with the desired molecular mass, identified using Matrix-assisted118
laser desorption ionisation-time of flight (MALDI TOF) mass spectrometry (MS),119
were pooled and lyophilised using a Genevac HT 4X (Genevac Ltd. Ipswitch, United120
6Kingdom). The peptides were dissolved in 70% (vol/vol) isopropanol at a121
concentration of 5 mg/ml and stored at -20°C under nitrogen. Appropriate dilutions of122
the peptides in 50 mM sodium phosphate buffer were used for bacteriocin assays.123
124
Specific activity determination. A microtiter plate assay system was used to125
determine the minimum concentration of salivaricin P required to inhibit growth of126
the indicator, L. innocua DPC3572 by 50% (MIC50). Each plate included triplicate127
assays at each concentration examined. Each well contained a total volume of 200 µl,128
comprised of purified Sln1 and purified Sln2 (or variants thereof), and 150 µl of a 1-129
in-10 dilution of the indicator culture (A590 of 0.1) in GM17 broth (supplemented with130
0.1% (vol/vol) Tween 80). Control wells contained media only (blanks), untreated131
indicator culture or the indicator treated with Sln1 or Sln2 alone. The microtiter plate132
cultures were then incubated for 6 h at 37°C and the optical density at 590 nm (OD590)133
was recorded at 0 h and 6 h (GENios plus; TECAN, Switzerland). Triplicate readings134
were averaged and blanks were subtracted from these readings. The amount of135
bacteriocin that inhibited the indicator strain by 50% was defined as 50% of the final136
OD590 ± 0.05 of the untreated control culture. The individual concentrations of Sln1137
and Sln2, which in combination inhibited the growth of L. innocua DPC3572 by 50%,138
were plotted as an isobologram. The point of intersection of the concentration of Sln1139
and Sln2 determines the specific activity of the peptides as well as the optimal peptide140
ratio for activity.141
142
Sequential treatment of L. innocua DPC3572 with salivaricin P143
component peptides. The sequential Sln1 and Sln2 treatment of the indicator L.144
innocua DPC3572, and vice versa, was assayed similarly to the procedure described145
7by Morgan et al., 2005 (21). The L. innocua cultures (in triplicate) were diluted 1 in146
10 and 150 l of each culture was added to 500 l microfuge tubes which contained147
Sln1 or Sln2 individually (at concentrations of 0 nM, 40 nM, 80 nM, 120 nM, 160 nM148
and 200 nM). Tubes were left at room temperature for approximately 20 min (to149
enable binding of peptide molecules to cell surfaces) prior to centrifuging at 13,000 150
g for 30 seconds. Supernatants were removed from each tube and cell pellets were151
washed twice with GM17 broth (supplemented with 0.1% (vol/vol) Tween 80). Cell152
pellets were resuspended in 150 l of fresh broth. Cells that had been exposed to Sln1153
alone were added to microtiter wells which contained Sln2, and cells that had been154
exposed to Sln2 alone were added to microtiter wells which contained Sln1 (at155
concentrations of 0 nM, 40 nM, 80 nM, 120 nM, 160 nM and 200 nM). Microtiter156
plates were incubated at 37ºC and read at hourly intervals for 6 hours, with the first157
reading representing time zero. Controls included expos cells to Sln1 and Sln2 in158
combination.159
160
Activity of trypsin resistant bacteriocin variants. Sln1, Sln2 and their161
respective variants were digested using trypsin gold (Promega Corporation, Madison,162
USA) according to the manufacturer’s instructions. Digestion of the peptides was163
confirmed by MALDI-TOF MS analysis. The MIC50 of each variant was assessed by164
combining with the wild-type peptide using the microtiter based assay system165
described above. The variants displaying lowest MIC50 when combined with the wild-166
type complementary peptide were then similarly combined with one another to167
determine their specific antilisterial activity.168
169
Results170
8Sln1 and Sln2 are active at nanomolar concentrations in an optimal ratio171
of 1:1. The salivaricin P peptides, Sln1 and Sln2, were generated by peptide synthesis.172
MS analysis confirmed that the masses of the synthetic peptides were identical to173
those produced by Lb. salviarius DPC6005 and antimicrobial activity assays using174
Listeria as the indicator established that the natural and synthetic peptides have equal175
potency. The combined concentrations of Sln1 and Sln2 that were required to inhibit176
the growth of the indicator strain, L. innocua DPC3572, by 50% were plotted as an177
isobologram (Fig. 1). As is the case for another class IIb bacteriocin, lactococcin G178
(22), the addition of Tween 80 to the culture medium (final concentration, 0.1%179
[vol/vol]) increased the assay sensitivity almost 10-fold (data not shown), and thus180
was incorporated in all cases. When assessed individually both Sln1 and Sln2181
displayed activity at micromolar concentrations against L. innocua DPC3572.182
However, Sln1 (MIC50 of 5M) has ten-fold higher individual activity than Sln2183
(MIC50 of 50 M). Studies with combinations of these peptides revealed that activity184
was optimal when Sln1 and Sln2 were combined at equal concentrations. This optimal185
ratio is consistent with that reported when the synthetic components of salivaricin186
CRL1328, with which salivaricin P shares 95% identity (Fig. 2), were tested using an187
Enterococcus faecalis indicator strain (32). Here we also establish that when Sln1 and188
Sln2 are combined the corresponding MIC50 value is 50 nM (Fig. 1), one hundred-fold189
more active than Sln1 alone.190
191
Salivaricin P peptides act sequentially to kill target cells at nanomolar192
concentrations. The Sln1 and Sln2 peptides were subjected to further investigation in193
order to determine whether or not they function in a sequential manner. It was194
apparent that growth inhibition was not observed when L. innocua DPC3572 was first195
9exposed to Sln1, followed by extensive washing and subsequent addition of Sln2.196
However, when the indicator was pre-treated with Sln2, prior to extensive washing197
and subsequent addition of Sln1, the degree of inhibition was comparable to that198
achieved when both peptides were added simultaneously (Fig. 3). This confirms a199
sequential mode of action and suggests that Sln2 is likely to be the receptor binding200
component of the bacteriocin.201
202
Design of salivaricin P variant peptides. Trypsin is predicted to specifically203
cleave at two locations in Sln1, i.e. after both Lys1 and Arg2, which would result in a204
43 amino acid (aa) product with a molecular mass of 3812 Da. It is also predicted to205
cleave at two locations in Sln2, after Lys1 and Arg10, which would result in a 9 aa206
fragment of 880 Da and 36 aa fragment of 3293 Da. These predictions were207
confirmed by MALDI-TOF MS analysis of the peptides before and after tryptic208
digestion (Table 2), and the effect of trypsin digestion on the activity of salivaricin P209
is presented in Figure 4. The residues that are lost as a consequence of trypsin210
digestion are, due to their cationic nature, likely important for bacteriocin activity. In211
both class I and class IIa bacteriocins these residues have frequently been found to212
play an important role in mediating the initial interaction with the anionic target cells213
via electrostatic interactions (3, 4, 17). Indeed, recent studies with the most214
extensively studied class IIb bacteriocin, lactococcin G, also revealed an important215
role for such residues in positioning the cationic C-termini of the bacteriocin216
components inside the target cell (23, 25, 27). Here we sought to maintain the potent217
antilisterial activity of the salivaricin P components while establishing a trypsin218
resistant phenotype. Therefore, to preserve the function of the positively charged219
trypsin-specific residues of salivaricin P, a variety of conservative changes to Sln1220
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and Sln2 were investigated (Table 1). These alterations included the removal and/or221
replacement by histidine of the trypsin-sensitive Lys and Arg residues as well as the222
insertion of proline residues adjacent to trypsin-specific sites to hinder the protease223
activity. Initially, the creation of Sln1-1, which lacks an N-terminal Lys, was224
synthesized in order to reveal the impact of partial trypsin digestion on the specific225
anti-Listeria activity of Sln1. A number of other peptides were also designed with a226
view to enhancing trypsin resistance. These included Sln1-2, a variant of Sln1227
containing a His rather than Lys1-Arg2 at the N-terminus, as well as Sln1-3 and Sln1-228
4, both of which contain His residues in place of either Lys1 or Arg2 in addition to the229
insertion of a proline residue adjacent to the other trypsin-sensitive residue. Sln1-5230
was also designed to include an additional Pro residue after the N-terminal Lys,231
together with the removal of a glycine such that both trypsin-sensitive residues are232
bordered at the carboxyl side by a proline. With respect to Sln2, a variant which233
contained an Arg10His substitution, Sln2-1, was predicted to confer trypsin resistance234
at this location in Sln2. However, this variant retains a trypsin cleavage site at Lys1,235
digestion of which is predicted to result in a 45 aa product of 4137 Da. Sln2-2 and236
Sln2-3 were designed to address this by combining the Arg10His substitution with a237
Pro insertion at the carboxyl side of Lys1 or a Lys1His substitution, respectively. Two238
truncated derivatives of Sln2 were also synthesized, Sln2-4, consisting of the 10 N-239
terminal aa fragment cleaved upon tryptic digestion of Sln2, and Sln2-5, which lacks240
the nine N-terminal amino acids of Sln2 but contains a Pro insertion following the241
now N-terminally located Arg residue.242
243
Activity and protease resistance of Sln1 variants. The variants described244
above were each synthesized and purified. The activity was assessed against L.245
11
innocua DPC3572 by combining each variant in equimolar concentrations with the246
wild-type version of the complementary peptide (Table 1). MS analysis was247
performed to assess the trypsin sensitivity of each of the synthetic variants (Table 2).248
This revealed that the purified Sln1 peptide and variants thereof are very sensitive to249
oxidation (as demonstrated by an associated 16 Da increase in the molecular mass of250
the peptide) which negatively impacted on antimicrobial activity. Studies with Sln1-1251
revealed that the N-terminal Lys of the peptide is not essential as the MIC50 of Sln1-1,252
when combined with Sln2, was 80 nM. However, as expected, this peptide remains253
susceptible to tryptic digestion, which results in a 3812 Da cleavage product (Table254
2). When this change was coupled with an Arg2His alteration to generate the trypsin255
resistant variant Sln1-2 (Table 2), the corresponding peptide was now four-fold less256
active (MIC50 of 200 nM) than Sln1 (MIC50 of 50 nM), when combined with Sln2.257
Crucially, however, this peptide had a trypsin resistant phenotype. These MIC50 values258
were further improved to 100 nM and 130 nM in the trypsin resistant peptides Sln1-3259
and Sln1-4, respectively (Table 2). However, of all the trypsin-resistant Sln1 variants,260
Sln1-5 was most impressive in that its potency against L. innocua DPC3572 is261
comparable to that of wild type Sln1, exhibiting a MIC50 of 80 nM (when combined262
with Sln2).263
Finally, as noted above, the Sln1 peptide and its variants are susceptible to264
oxidation. This phenomenon has previously been associated with a number of other265
class II bacteriocins (13, 16, 20) and has been attributed to the oxidation of the266
sulphur atom of methionine residues resulting in the formation of methionine267
sulfoxide. To determine if the oxidation of Sln1 is due to the methionine residue at268
position 37 an additional Sln1 variant, Sln1-6, which contains a Met37Leu269
substitution, was generated. Although the activity of this variant was reduced by more270
12
than two-fold (MIC50 of 120 nM), compared to that of the wild type, thereby271
indicating the importance of this methionine residue for activity, this variant did not272
display susceptibility to oxidation, confirming that the Met37 residue is the oxidation-273
sensitive residue.274
275
Activity and protease resistance of Sln2 variants. Trypsin also cleaves at276
two sites within Sln2 resulting in the removal of Lys1 as well as a further nine aa N-277
terminal fragment upon cleavage at Arg10 (Table 2). Substitution of Sln2Arg10 with278
His (Sln2-1) resulted in a four-fold decrease in activity when combined with wild type279
Sln1 (Table 1). An associated cleavage product of 4137 Da upon tryptic digestion280
(Table 2) confirmed trypsin resistance at this position. When this modification was281
coupled with the insertion of a Pro residue following Lys1 (Sln2-2), complete trypsin282
resistance was achieved without further reducing antimicrobial activity (Tables 1 and283
2). However, substituting Lys1 as well as Arg10 with His (Sln2-3) also resulted in284
trypsin resistance (Table 2) and led to an improvement in specific activity (MIC50 of285
120 nM), when combined with wild-type Sln1. The 10 N-terminal aa fragment of Sln2286
(Sln2-4) did not display anti-Listeria activity. However, although the specific activity287
of the trypsin resistant Sln2-5 variant (Table 2) was reduced five-fold relative to Sln2288
(again when combined with Sln1; Table 1), it retained a similar spectrum of activity,289
inhibiting species of Lactobacillus, Enterococcus and Listeria (as determined by well290
diffusion assay; Fig. 5). It is thus apparent that the nine N-terminal residues of Sln2291
are not essential for peptide function.292
293
Specific activity of combined trypsin resistant variants (Sln1-5 and Sln2-294
3). The specific activity determinations using a combination of the two most potent,295
13
trypsin-resistant peptides, Sln1-5 and Sln2-3, revealed that their combined specific296
activity (MIC50 of 300 nM) was just 3.75-fold less than that of the wild type peptides297
(80 nM) against L. monocytogenes NCTC 11994 (Fig. 6).298
299
Discussion300
The naturally occurring two component bacteriocins, salivaricin P, abp118 and301
salivaricin CRL1328 share greater than 95% homology (2, 12, 32). While these302
bacteriocins have shown promise in controlling intestinal pathogens in situ, a303
fundamental understanding of how these peptides function is crucial, both in terms of304
gaining regulatory approval for such applications and to assist in the design of305
antimicrobial derivatives with improved functionality. Recent studies revealed the306
pore forming ability of salivaricin CRL1328, and thus presumably of salivaricin P and307
abp118, results in dissipation of both the transmembrane electrical potential and the308
pH gradient of sensitive cells (32). While the synthetic salivaricin P components309
display weak individual activity, this study confirmed that optimal synergistic310
antimicrobial activity is achieved when the component peptides are combined at311
nanomolar concentrations in a ratio of 1:1. We also demonstrated that the individual312
peptides function in a sequential manner and it is established that Sln2, but not Sln1,313
is capable of binding to the target cell membrane in the absence of its companion314
peptide. While it is likely that this involves an interaction with a docking molecule or315
receptor, studies of Sln2 peptides with altered chirality will be required to verify the316
existence of a cellular receptor for Sln2. The subsequent addition of Sln1, to317
potentially form a bacteriocin-membrane receptor complex, is then required for318
optimal activity.319
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A variety of alterations of each of the component peptides were designed,320
created and assessed with a view to enhancing the trypsin-resistance of salivaricin P321
without dramatically reducing the antimicrobial activity of the bacteriocin. It was322
noted that, in general, insertion of proline residues represented a very well tolerated323
means of generating trypsin-resistant salivaricin variants. The least deleterious Sln1324
variant was that in which both trypsin-sensitive residues were present (Sln1-5), with325
adjacent proline residues introduced to confer trypsin resistance. While a comparable326
Sln2 variant was not generated, it was noted that an additional proline insertion in327
Sln2-2 did not further reduce its activity relative to Sln2-1, which like Sln2-2 also328
contained an Arg10His substitution. In contrast, the most deleterious mutation of Sln1329
involved a single histidine substitution of both trypsin-sensitive residues (Sln1-2).330
Conversely, the conservative histidine substitution of both trypsin-sensitive residues331
of Sln2 was well tolerated, with the corresponding variant, Sln2-3, being the most332
active of all of the Sln2 variants. Assays with purified Sln1 peptides revealed a333
consistent tendency for the peptides to become oxidised. It was established that this334
oxidation occurred at Met37 and was absent in a Met37Leu variant of Sln1. The335
reduced activity of the corresponding Sln1-6 peptide revealed that the methionine is336
required for optimal activity, perhaps being required to facilitate correct peptide337
folding or for the interaction of Sln1 with Sln2 or the target cell membrane.338
Analysis of the trypsin-resistant N-terminally truncated derivative of Sln2,339
Sln2-5, revealed that while these changes were deleterious, the truncated variant340
continued to exhibit anti-listerial activity at nanomolar concentrations and possessed a341
similar spectrum of inhibition to Sln2, when combined with Sln1. This finding is342
significant given that, on the basis of the sequential action studies, it is necessary for343
Sln2 to first bind to target cells and it is thus likely to be responsible for determining344
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target cell specificity. Interestingly, the natural salivaricin P variant, abp118, differs345
from Sln2 with respect to two C-terminal amino acid changes (Ala43Thr and346
His46Arg). The fact that the spectrum of inhibition of salivaricin P and abp118 also347
differ (2), suggests the potential involvement of the C-terminal region of this peptide348
in determining target cell specificity. Further alterations of the C-terminal residues of349
Sln2 will be investigated to address this. Significantly, however, the variants350
generated here demonstrate that a variety of mutations can result in the creation of351
trypsin-resistant variants of the salivaricin P peptides without significantly altering the352
length, net charge and, most importantly, potency of the bacteriocin.353
Bacteriocins have great potential as antimicrobials for biopreservation and354
biomedicine-related applications. The inactivation of bacteriocins used as food355
biopreservatives by digestive enzymes, thereby preventing a detrimental impact on the356
commensal gut microbiota, is considered desirable. However, there are also instances357
where targeted antimicrobial activity in the gut is desirable, for example to inhibit358
specific pathogenic microorganisms. While strategies such as bioencapsulation and359
the exploitation of probiotics are attractive options to facilitate the in situ production360
of bacteriocins (as with the abp118 and salivaricin P producers Lb. salivarius361
UCC118 and Lb. salivarius DPC6005, respectively (5, 33)), the inherent protease362
sensitivity of these peptides remains an issue. In this study we demonstrate the363
potential to enhance the protective function of such salivaricin P-like bacteriocins.364
While we acknowledge that the trypsin-resistant variants described in this study will365
remain sensitive to other proteases encountered in the GIT, they represent an366
important step forward in that it is now apparent that such beneficial traits can be367
incorporated in a deliberate manner. These developments can in turn be incorporated368
into the producing strain by site-directed mutagenesis for assessment of their efficacy369
16
in vivo, resulting in the ultimate creation of protease-resistant anti-Listeria370
antimicrobials with an associated bacterial-based delivery system.371
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Figure Legends507
Figure 1. Concentrations of Sln1 and Sln2 required to inhibit the growth of the508
indicator strain, Listeria innocua DPC3572, by 50%.509
510
Figure 2. Alignment of the two component peptides of the natural bacteriocin variants511
salivaricin P (Sln1 and Sln2) (2), abp118 (Abp118α and Abp118β) (12) and512
salivaricin CRL1328 (Salα and Salβ) (32). Conservation of amino acid residues is513
indicated by * beneath the residue. Residues which are not conserved are underlined.514
The component peptides of abp118 and salivaricin CRL1328 are 100% identical. Sln1515
shares 100% identity with the corresponding peptides of abp118 and salivaricin516
CRL1328 while Sln2 shares 95% identity with its abp118 and salivaricin CRL1328517
counterparts.518
519
Figure 3. Effects of sequential addition of the Sln1 and Sln2 peptides on the growth520
of the indicator strain, Listeria innocua DPC3572 (A) Sln1 followed by Sln2 addition;521
(B) Sln2 followed by Sln1 addition, and (C) Sln1 and Sln2 simultaneously.522
Concentrations of 0 nM (Δ), 40 nM (x), 80 nM (●), 120 nM (▲), 160 nM (◊), and 200 523
nM () were used. Error bars represent standard deviations on triplicate data. 524
525
Figure 4. The antimicrobial activity of salivaricin P (A) before and (B) after a 3 hour526
trypsin digestion reaction, against Listeria innocua DPC3572. (A) The top left well527
contains Sln1 alone, the top right well contains Sln2 alone and the bottom well528
contains Sln1 and Sln2 combined in equal amounts. (B) The top left well contains529
Sln1 treated with trypsin, the top right well contains Sln2 treated with trypsin and the530
bottom well contains trypsin treated Sln1 and Sln2 combined in equal amounts.531
23
532
Figure 5. Individual and combined antimicrobial activity of Sln1 and Sln2-5. In each533
panel the top left well contains Sln1 alone, the top right well contains Sln2-5 alone534
(both at 50 µM concentrations) and the bottom well contains Sln1 and Sln2-5535
combined in equal amounts against (A) E. faecalis DPC1142, (B) Lb. bulgaricus536
LMG 6901 and (C) L. innocua DPC3572.537
538
Figure 6. Effect of (A) wild-type salivaricin P at concentrations of 0 nM to 250 nM539
and (B) trypsin resistant Sln1-5 and Sln2-3 variants at concentrations of 0 nM to 500540
nM against Listeria monocytogenes NCTC11994.541
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Table 1. Sequences and MIC50 of the salivaricin P component peptides and their542
variants against L. innocua DPC3572543
Peptide Amino acid sequencea
Length
(aa)
MIC50b
(nM)
Sln1 K R GPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL 45 50
Sln1-1 R GPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL 44 80
Sln1-2 H GPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL 44 200
Sln1-3 KPH GPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL 46 100
Sln1-4 HRPGPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL 46 130
Sln1-5 KPR PNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL 45 80
Sln1-6 K R GPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGLVGGALTCL 45 120
Sln2 K NGYGGSGNR WVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH 46 50
Sln2-1 K NGYGGSGNH WVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH 46 200
Sln2-2 KPNGYGGSGNH WVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH 47 200
Sln2-3 H NGYGGSGNH WVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH 46 120
Sln2-4 K NGYGGSGNR 10 -
Sln2-5 RPWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH 38 250
aThe carboxyl side of lysine (K) and arginine (R) represent trypsin specific cleavage sites.
bMIC50 of bacterioicn variant combined with wild type complementary peptide.
25
Table 2. Impact of tryptic digestion of Sln1 and Sln2 and their respective variants as544
determined by mass spectrometry545
Peptide
Molecular
Mass (Da)
Mass (Da) following
3 hr trypsin digest Trypsin sensitivitya
Sln1 4,096 3,812 S
Sln1-1 3,968 3,812 S
Sln1-2 3,949 3,949 R
Sln1-3 4,174 4,174 R
Sln1-4 4,202 4,202 R
Sln1-5 4,136 4,136 R
Sln1-6 4,078 3,812 S
Sln2 4,284 880, 3,293 S
Sln2-1 4,265 4,137 S
Sln2-2 4,362 4,362 R
Sln2-3 4,274 4,274 R
Sln2-4 1,009 880 S
Sln2-5 3,547 3,547 R
a S, sensitive; R, resistant.546
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Sln1 KRGPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL550
Abp118α KRGPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL551
Salα KRGPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL552
*********************************************553
554
Sln2 KNGYGGSGNRWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH555
Abp118β KNGYGGSGNRWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFTSCR556
Sal β KNGYGGSGNRWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFTSCR557
****************************************** **558
Figure 2.559
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Figure 5.575
Indicator strain
(A) Enterococcus faecalis DPC1142
(B) Lactobacillus bulgaricus LMG 6901
(C) Listeria innocua DPC3572
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